Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Shaping Innovative Designs for Sustainable Tissue Engineering Products (SHIFT)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Research and innovation staff exchange
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Australia,Italy,Korea, Republic of,Mongolia,Malaysia,Thailand,United Kingdom,Portugal
Call: Research and Innovation Staff Exchange (H2020-MSCA-RISE-2020, 2020)
Start date: 2021-09-01
End date: 2025-08-31
Duration (months): 48.0
Total project cost (EUR): 1085600.0
EU funding (EUR): 910800.0
Participants: 8
Project status: SIGNED

Shaping Innovative Products for Sustainable Tissue Engineering Strategies - SHIFT is the follow up of MSCA-RISE REMIX (GA 778078). While REMIX researched and confirmed the potential of natural origin material such as silk proteins, collagen, keratin and marine organism-derived polymers for use in Tissue Engineering and Regenerative Medicine, SHIFT aims to take the research a step forward and design innovative natural-based, scalable constructs that enhance angiogenesis for the treatment of widespread chronic pathologies, such as large defect in bone and cartilage and the treatment of chronic wounds (ex. diabetic ulcer). Prototypes will be fabricated considering scalability, costs, regulatory issues. Multiple strategies will be used to achieve this aim: - pre-assessment of the regulative framework for TERM products and close collaboration with the industry; - fabrication in accordance with current GMP and ISO quality management Systems-requirements - standardization of the protocols for purification of raw materials from the waste of textile and food industry for the production of these prototypes, using medical-grade, commercially-available raw materials as benchmark. This may lead to the opening of a new opportunity for re-using industrial waste which is currently disposed of. - application of the principles of Green Chemistry to reduce the environmental impact of the research and production of the prototypes. An extensive training program will be offered to ESRs to set the best conditions for successful performance. The program will be offered through summer schools and online seminars and will cover a variety of topics related to TERM, technologies, regulations for product development. A special highlight will be devoted to product-development, spin-off, venture capitals, to provide junior researchers with knowledge and skills that may allow them to become profiles capable to successfully transfer ideas and innovations from academia to the industry.

Keywords: tissue engineering,regenerative medicine,product design,green chemistry,wound healing,bench to bedside,biotechnology,bone,cartilage
Impact of medical drugs on the evolution of human microbiome function and antimicrobial resistance development (DIMEvAR)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Career Restart panel
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany
Call: Individual Fellowships (H2020-MSCA-IF-2020, 2020)
Start date: 2021-04-01
End date: 2024-03-31
Duration (months): 36.0
Total project cost (EUR): 262209.6
EU funding (EUR): 262209.6
Participants: 1
Project status: SIGNED

The human gastrointestinal tract harbors trillions of microbes, known as the gut microbiota. This microbial community helps modulating developmental, immunological, and metabolic functions of the human host and it plays an important role in medicinal drug response. Several works showed the bidirectional relationship between the gut microbiota and drugs. Medication modifies microbiome composition both in vitro and in the human gut. Further, commonly used drugs influence the microbiome metabolic functions and increase the abundance of antimicrobial resistance (AMR) genes in human cohort studies, suggesting that non-antibiotic drugs could contribute to the emergence of AMR. At the same time, microbiome-encoded enzymes can metabolize a wide range of medical drugs, participating in both beneficial and adverse effects. Considering that many drugs are used over extended periods of time to treat chronic diseases, long-term exposure to drugs may likely drive microbiome evolution. This could influence and evolve metabolic properties of gut microbes and lead to the emergence of novel AMR. This project aims at better understanding the impact of long-term exposure to medical drugs on human gut microbiome evolution at the phenotypic and metabolic level, the underlying molecular mechanism, and their consequences in vivo. Based on previous data and in analogy to well-understood antibiotics, I hypothesize that non-antibiotic drugs might induce stress-triggered microbial evolution. The project follows three specific objectives: (i) Quantify the impact of drug-induced evolution on microbiome metabolism and antibiotic sensitivity; (ii) Determine the role of bacterial stress responses in microbiome evolution; (iii) Assess drug-induced microbiome evolution using gnotobiotic mouse models. If successful, this work will reveal the molecular mechanisms underlying microbiome-drug interactions and pave the way for their rational modulation to improve current and future drug therapies.

Keywords: gut microbiome,microbiome evolution,antimicrobial resistance,bacterial mutagenesis,drug metabolism
NEW GENERATION OF HIGH VALUE-ADDED ANTIOXIDANT FOOD INGREDIENTS FOR THE GOURMET CUISINE (VINESENTI)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Action type: SME instrument
Countries involved: Spain
Call: Resource-efficient eco-innovative food production and processing (H2020-SMEINST-1-2014, 2014)
Start date: 2015-05-01
End date: 2015-10-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

In recent years, we have been witnessing a boom of gastronomic themes and a constant and continuous emergence of new and sophisticated food products in contrast with the simplicity of the traditional cuisine. There are around 2,000 Michelin Star restaurants and more than 20,000 high standing restaurants all over the world. The competitiveness in this sector is very high and there is a necessity of differentiation from the competence, looking for new flavours, aromas and textures that allow their dishes to have high value-added. VINESENTI is a natural product obtained from the valorisation of grape pomace, a winery by-product. It is a concentrate reddish or ochre powder, depending on the grapes that it comes from, red or white grapes. It has been designed to enhance and enrich recipes because of its benefits related to improvements in the sensory profile, textures and shelf life of dishes. Specifically, this product provides freshness, spiced flavours, sweet tannins and fruity sensations. The main objectives of the Phase 1 of SME Instrument are to study, evaluate and redefine, if necessary, the different factors of VINESENTI project in order to carry out the Phase 2 successfully. To achieve these objectives, Abro Biotec will carry out a feasibility study which could be divided into the following tasks: a technical study, a market analysis and customer discovery, an economic study and the IPR strategy and legal issues. VINESENTI will suppose a new niche market for the company because up to now, pharmaceutical and cosmetic industries have been the main end-users of the grape polyphenolic extract; but in the future, restaurants, food companies and people in general will be a new market segment. In consequence, a growth of the company will be achieved and this will result in an increase of its competitiveness, turnover and in job creation.

Keywords: by products,wine,grape,grape pomace,food additive,food ingredient,vinesenti
Thermometry and Photoacoustic-Imaging Outstanding Nanoprobes (TEMPTATION)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Global Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: United States,Portugal
Call: Marie Skłodowska-Curie Individual Fellowships (IF-GF) (H2020-MSCA-IF-2015, 2015)
Start date: 2017-04-01
End date: 2019-12-26
Duration (months): 32.0
Total project cost (EUR): 207759.8
EU funding (EUR): 207759.8
Participants: 2
Project status: CLOSED

This project addresses the quest of new materials and approaches that nanotechnology requires to solve the current limitations of medicine. The potential to externally track and image organs and the potential presence and evolution of diseases by using light becomes a reality thanks to the use of especially tailored biocompatible nanoplatforms. New avenues to image living bodies by light allied with mechanical waves (i.e. sound) are going to be opened. We propose here an elegant marriage between light and sound endowing smartly designed nanoprobes with the capability of deep-tissue photoacoustic imaging, also accompanied by all-optical temperature sub-tissue measuring. To increase the penetration depth and spatial resolution, an imaging approach pumping the probes with near-infrared light is proposed. Therefore, we propose a kind of material no previously exploited for photoacoustic exogenous agent, working as bimodal nanoprobe by also optically measuring temperature within the biological transparency windows in the near-infrared

Keywords: photoacoustic imaging,nanothermometry,surface functionalization
Endeavour Space Hub (SPACE END)

Framework: Horizon 2020 — Industrial Leadership
Programme: Space
Theme: Enabling European competitiveness, non-dependence and innovation of the European space sector
Action type: Coordination and support actions
Countries involved: Spain,Spain,Romania,Romania,France
Call: Space hubs (support to start-ups) (H2020-SPACE-2019, 2019)
Start date: 2019-11-01
End date: 2021-12-31
Duration (months): 26.0
Total project cost (EUR): 1039230.0
EU funding (EUR): 1034230.0
Participants: 6
Project status: CLOSED

The overall aim is to expand the impact and adoption of Space Tech by bringing together Space start-ups, SMEs, entrepreneurs and the IoT ecosystem to increase commercial relevance of the technologies across industrial sectors and accelerate their access to market and/or scaling. We will achieve this by designing and orchestrating a collaborative ecosystem with adapted tools and instruments that will position a greater number of space-enabled technologies in industrial markets. This ecosystem will be based on a blended community of IoT and Space that brings together a range of stakeholders, large and small, from academia, business and the public sector not just across the three local ecosystems that are directly taking part. The specific objectives are to: • Identify promising tech generated within the European space ecosystem that are susceptible to being used in Industry. • Identify SMEs, tech start-ups and founders who could benefit from space technologies through a range of local activities. • Design and deliver an acceleration programme for early stage space and IoT tech companies. • Facilitate access to innovative financial support to them consolidate their market offering and grow. • Increase the commercialisation and industry adoption of space tech. • Create a Europe-wide network of Space entrepreneurs . We will start by scouting promising space technologies that can be brought to market from across Europe. Their market relevance will be explored by stakeholders through locally delivered design studios. The ventures with the greatest potential will then be supported through an intensive 3+3 month acceleration programme than will build the founders capacity and further enable them to build and implement their go to market strategies. Over the 2 year period, t240 space and data technologies will be explored; the market potential of 90 of these will be scrutinised and 30-45 startups/ventures will have been helped to scale.

Keywords: start ups,commercialisation of space technologies,space tech ecosystems
First anti-fraud plataform for the registration and certification of diplomas and academic certificates based in blockchain (SmartDegrees)

Framework: Horizon 2020 — Industrial Leadership
Programme: Innovation in SMEs
Action type: SME instrument
Countries involved: Spain
Call: SME instrument (H2020-SMEInst-2018-2020-1, 2019)
Start date: 2020-01-01
End date: 2020-06-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

The higher education sector is one of the most attractive and growing sectors1, but is undergoing profound changes, due to disruptive innovations, such as the online and corporate “universities”, in addition to sustaining ones related to the Internet, mobile phones and new technologies. To avoid disruption, the universities must develop innovation strategies. The model of traditional universities has become unsustainable The academic degrees are an example of the existing obsolescence, since its support in paper limits the value to the user accessing the labor market, whose processes are digital. The university is changing and blockchain will be key, which will be the most important and most disruptive technology for education, allows: (i) Address current job-to-be-done in degrees: enhancement, digital support, (ii) Add other opportunities, such as user's digital identification, (ii) Expansion to other sectors, such as healthcare. SmartDegrees provides a unique platform addressing a new business model for the registration and certification of academic degrees, in blockchain to secure and provides an efficient process for all stakeholders (academic institutions, companies and graduates) SmartDegrees converts the degree in a digital asset secure and dynamic in the profesional and social life of people.

Keywords: blockchain,certifications,degrees,universities,tertiary education,anti fraud
Pushing the boundaries of Cost and Outcome analysis of Medical Technologies (COMED)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Methods and data
Action type: Research and Innovation actions
Countries involved: Germany,Italy,Switzerland,Hungary,Netherlands,United Kingdom,United Kingdom
Call: Methods research for improved health economic evaluation (H2020-SC1-2017-Single-Stage-RTD, 2017)
Start date: 2018-01-01
End date: 2021-06-30
Duration (months): 42.0
Total project cost (EUR): 3017025.0
EU funding (EUR): 3017025.0
Participants: 8
Project status: CLOSED

The overarching objective of the COMED project is to push the boundaries of existing methods for cost and outcome analysis of healthcare technologies, both within the Health Technology Assessment (HTA) and Health System Performance (HSP) frameworks and to develop tools to foster the use of economic evaluation in policy making. Within this general agenda, the COMED project focuses on one broad category of healthcare technologies (medical devices) for exemplary, empirical purposes to: (i) improve economic evaluation methods for medical devices in the context of the HTA framework by increasing their methodological quality and integrating data from different data sources; (ii) investigate health system performance through analysis of variation in costs and outcomes across different geographical areas and (iii)strengthen the use of economic evaluation of medical devices in policy making. COMED’s ambition is to develop scientifically rigorous recommendations on what, when and how real world evidence sources can and should be used for assessment of medical devices. COMED’s aim is to develop new methods for assessing patient reported outcomes for mHealth technologies. COMED will provide a comprehensive answer on the main drivers of clinical practice variations across Europe by differentiating between warranted and unwarranted causes of disparities. COMED will develop, for the first time, adequately researched policy advice for the early assessment and conditional reimbursement policy tools in the field of medical devices. The project will expand the geographic scope of evidence generation from a single jurisdiction to collaborative evidence generation throughout Europe. It will have a substantial impact by on public health in Europe, by providing scientifically robust evidence for a wide range of key stakeholders ranging from policy makers to patients and wider public

Keywords: medical devices,real world data,mhealth,surrogate outcomes,clinical practice variation,early assessment,coverage with evidence development,transferability
Sexual dimorphIsM in renal PrOgenitors to explain gender- Specificity In kidney physiOlogy aNd diseases (SIMPOSION)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Physiology in Health, Disease and Ageing
Panel description: Organ and tissue physiology, comparative physiology, physiology of ageing, pathophysiology, interorgan and tissue communication, endocrinology, nutrition, metabolism, interaction with the microbiome, non-communicable diseases including cancer (and except disorders of the nervous system and immunity-related diseases)
Countries involved: Italy,Denmark
Call: ERC ADVANCED GRANT (ERC-2020-ADG, 2020)
Start date: 2021-08-01
End date: 2026-07-31
Duration (months): 60.0
Total project cost (EUR): 2296900.0
EU funding (EUR): 2167456.25
Participants: 2
Project status: SIGNED

Kidney disorders represent a major global health burden with a significant sexual dimorphism that is largely unexplained. My group first identified the stem cells of the kidney (renal progenitors) and demonstrated their crucial role in kidney disease. Here, I propose that sex hormones regulate number and function of renal progenitors to empower females to face the hemodynamic and metabolic challenges of pregnancy. I further propose that this process impacts on sexual dimorphisms in incidence and outcome of kidney diseases including kidney cancer. A multitude of unpublished data obtained with primary human progenitor cultures and unique mouse models of progenitor-specific sex hormones receptor knockout already support my concepts. I will demonstrate that, starting from the age of fertility, estrogen signaling in renal progenitors supports their survival and self-renewal, which is needed to increase their capacity to generate new podocytes and tubular epithelial cells. I will show that failure to produce a sufficient number of podocytes from estrogen-activated renal progenitors promotes preeclampsia and fetal growth retardation. This is a completely new pathophysiological concept of why women with a mismatch of nephron number and pregnancy-related hyperfiltration develop preeclampsia. I will further demonstrate that the same mechanism protects fertile women from severe forms of glomerular injury unrelated to pregnancy. Finally, I will prove that to compensate for the lower number of renal progenitors, testosterone pushes them to proliferate more in males and that this can explain the increased incidence of most prevalent forms of kidney cancer, that derive from renal progenitors. This topic is a direct continuation of my previous studies on renal progenitors supported by ERC Starting and Consolidator grants and will unravel fundamental paradigms in kidney physiology, adaptation, and disease with important implications for prevention and management of kidney disease.

Keywords: kidney,renal cell carcinoma,pregnancy,renal progenitor
Developing Novel and Optimal Additive Solutions for Red Blood Cells (DENOVO-RBC)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Proof of concept grants
Action type: ERC actions
Countries involved: Iceland
Call: ERC Proof of Concept Grant (ERC-2014-PoC, 2014)
Start date: 2015-03-01
End date: 2016-08-31
Duration (months): 18.0
Total project cost (EUR): 150000.0
EU funding (EUR): 150000.0
Participants: 1
Project status: CLOSED

The research conducted in SYSTEM_US (ERC Advanced Grant #232816) has led to the discovery of valuable biomarkers for the quality of red blood cells (RBCs) in standard blood bank storage conditions. Using a combination of systems biology and metabolomics, this discovery will lead to the development of novel RBC storage technologies including additive solutions and diagnostics. These technologies will become valuable assets in the form of intellectual property to large transfusion medicine companies and will save thousands of lives over the coming decades. This proposal covers the needs to fully define the market and NPV of the developing technology, fully define the regulatory and clinical path of product approval, file for patents to protect the intellectual property, conduct necessary validation experiments, and continue to develop relations with industry contacts.

Keywords: transfusion,transfusion medicine,blood banking,blood,red blood cells,blood storage,additive solutions,diagnostics,metabolism,metabolomics,systems biology
Best markets for the exploitation of innovative sustainable food packaging solutions (MYPACK)

Framework: Horizon 2020 — Societal Challenges
Programme: Food security, sustainable agriculture and forestry, marine and maritime and inland water research and the bioeconomy
Theme: Sustainable and competitive agri-food sector for a safe and healthy diet
Action type: Innovation actions
Countries involved: Germany,Italy,Italy,Germany,Germany,Germany,Italy,Germany,Italy,Greece,Switzerland,France,France,France,Netherlands,Netherlands
Call: Innovative solutions for sustainable food packaging (H2020-SFS-2017-1, 2017)
Start date: 2017-11-01
End date: 2021-10-31
Duration (months): 48.0
Total project cost (EUR): 5757035.36
EU funding (EUR): 4649860.91
Participants: 21
Project status: CLOSED

Mypack general objective is to help sustainable food packaging technologies to reach or to extend their market. It will provide general guidelines to select the best market for a new technology and to ensure the best commercial development, through (i) the best environmental efficiency (direct impacts of packaging, food waste impacts, optimized recycling composting combusting end life, preserved consumer health), (ii) the best consumer acceptability, and (iii) an optimized industrial feasibility. In order to do so, 3 ambitious SMART key objectives with associated KPIs will be considered during the Mypack project to promote the commercial development of: - Biodegradable and compostable packaging. - Packaging from renewable resources. - Elaborated (high barrier and active) packaging technologies. Barriers and challenges are clearly identified and solutions to overcome them are presented. 7 innovative sustainable food packaging solutions are considered of which 5 will be developed and exploited. The sustainable food packaging state of the art is comprehensively described and it is made clear how Mypack solutions will extend beyond it. Appropriate measures, in line with the work program, were selected to maximize the impact of the project. Mypack project targets the scope of the call throughout this proposal and is thus fully in line with the call objectives. A convincing exploitation plan is presented in the form of 7 work packages, 5 of which are technical in nature. Appropriate milestones and risks are considered in order to complete the project objectives in the due time. The Mypack consortium is composed of 18 partners, covering the academic, scientific and industrial world, including SMEs. Major stakeholders have provided letters of intent, showing their interest in the Mypack approach which will have essential impact in order to define the best markets for the exploitation of innovative sustainable food packaging solutions.

Keywords: biodegradable and compostable packaging,packaging from renewable ressources,elaborated high barrier and active packaging technologies